Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma

Annals of Surgical Oncology

Volumn 12, Issue 12, 2005, Pages 1073-1083

  Lascelles, B Duncan X ^a   Dernell, William S ^b   Correa, Maria T ^a   Lafferty, Mary ^b   Devitt, Chad M ^b   Kuntz, Charles A ^b   Straw, Rodney C ^b   Withrow, Stephen J ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Canine; Limb salvage; Osteosarcoma; Postoperative infection

Indexed keywords

CARBOPLATIN; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOG; FEMALE; HAZARD ASSESSMENT; INFECTION; KAPLAN MEIER METHOD; LIMB SALVAGE; MALE; NONHUMAN; OSTEOSARCOMA; POSTOPERATIVE COMPLICATION; PROGNOSIS; RADIUS; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; WOUND INFECTION;

ANIMALS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOGS; FEMALE; HINDLIMB; LIMB SALVAGE; MALE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROPORTIONAL HAZARDS MODELS; RADIUS; SURGICAL WOUND INFECTION; SURVIVAL ANALYSIS;

EID: 27844513375     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2005.01.011     Document Type: Article

References (80)

1. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-50.
2. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma Dog versus man. Clin Orthop 1991;270:159-68.
3. Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-8.
4. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-60.
5. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
6. LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734-44.
7. Shapiro W, Fossum T, Kitchell B, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-11.
8. Spodnick G, Berg J, Rand W, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-9.
9. Maulin G, Matus R, Withrow S. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177-80.
10. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996;26:135-43.
11. Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990;18:1351-7.
12. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-64.
13. Schantz SP, Skolnik EM, O'Neill JV. Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. Otolaryngol Head Neck Surg 1980;88:412-7.
14. Sensenig DM, Rossi NP, Ehrenhaft JL. Pulmonary resection for bronchogenic carcinoma in geriatric patients. Ann Thorac Surg 1966;2:508-13.
15. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013-7.
16. Grandis JR, Snyderman CH, Johnson JT, et al. Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer 1992;70:2166-70.
17. Jackson RM, Rice DH. Wound infections and recurrence in head and neck cancer. Otolaryngol Head Neck Surg 1990;102:331-3.
18. Papachristou DN, Fortner JG. Effect of postoperative wound infection on the course of stage II melanoma. Cancer 1979;43:1106-11.
19. Higuchi Y. Antitumor effect of Streptococcus pyogenes by inducing hydrogen peroxide production. Jpn J Cancer Res 1996;87:1271-9.
20. Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004;11:705-13.
21. Straw RC, Powers BE, Withrow SJ, et al. The effect of intramedullary polymethylmethacrylate on healing of intercalary cortical allografts in a canine model. J Orthop Res 1992;10:434-9.
22. Dernell W, Withrow SJ, Straw RC, et al. Clinical response to antibiotic impregnated polymethyl methacrylate bead implantation of dogs with severe infections after limb sparing with allograft replacement; 18 cases (1994-1996). Vet Comp Orthop Traumatol 1998;11:94-9.
23. Sturgis EM, Congdon DJ, Mather FJ, Miller RH. Perioperative transfusion, postoperative infection, and recurrence of head and neck cancer. South Med J 1997;90:1217-24.
24. Kressner U, Graf W, Mahteme H, et al. Septic complications and prognosis after surgery for rectal cancer. Dis Colon Rectum 2002;45:316-21.
25. Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14:587-92.
26. Davis AM, Bell RS, Goodwill PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
27. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 1991;67:126-34.
28. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-705.
29. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-58.
30. Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998;213:1002-6.
31. Dick HM, Strauch RJ. Infection of massive bone allografts. Clin Orthop 1994;(306):46-53.
32. Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 1996;(324):86-97.
33. Gebhardt MC, Flugstad DI, Springfield DS, Mankin HJ. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. Clin Orthop 1991;(270):181-96.
34. Brown DC, Conzemius MG, Shofer F, Swann H. Epidemiologic evaluation of postoperative wound infections in dogs and cats. J Am Vet Med Assoc 1997;210:1302-6.
35. Dernell WS, Withrow SJ, Straw RC, et al. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997;17:4499-505.
36. Ehrhart N, Dernell WS, Ehrhart EJ, et al. Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice. Am J Vet Res 1999;60:1347-51.
37. Mnaymneh W, Malinin TI, Lackman RD, et al. Massive distal femoral osteoarticular allografts after resection of bone tumors. Clin Orthop 1994;(303):103-15.
38. Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Exp Musculoskel Res 1995;4:105-10.
39. Misdorp W, Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 1979;62:537-45.
40. Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990;72:643-53.
41. Bech-Nielsen S, Brodey RS, Fidler IJ, et al. The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma. Eur J Cancer 1977;13:33-41.
42. Eilber FR, Townsend C, Morton DL. Osteosarcoma. Results of treatment employing adjuvant immunotherapy. Clin Orthop 1975;(111):94-100.
43. Owen LN, Bostock DE. Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma. Eur J Cancer 1974;10:775-80.
44. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
45. Oettgen HF, Carswell EA, Kassel RL, et al. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res 1980;75:207-12.
46. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
47. Watanabe N, Niitsu Y, Yamauchi N, et al. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharmacol Immunotoxicol 1988;10:53-65.
48. Suzuki K, Tsuge I, Ito Y, et al. Histological effect of intranodal injection of the streptococcal preparation OK-432 for cervical lymph node metastases of malignant head and neck tumors. Acta Otolaryngol Suppl 1996;525:125-8.
49. Kimura T, Suzuki K, Motai H, et al. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Acta Otolaryngol Suppl 1996;525:135-41.
50. Taradi M, Urano M, Taradi SK, Maruyama Y. Augmentation of mouse natural killer cell activity by combined hyperthermia and streptococcal preparation, OK-432 (Picibanil) treatment. Int J Hyperthermia 1991;7:653-65.
51. Ozaki S, Suginoshita T, Watanabe T, Obayashi H. Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells. Cancer Res 1990;50:4630-4.
52. Asano T, McWatters A, An T, et al. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 1994;268:1032-9.
53. Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 1993;14:286-92.
54. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995;1:1595-601.
55. Youdim S. Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. J Immunol 1976;116:579-84.
56. Youdim S. Destruction of experimental malignant melanoma by mediators of cellular immunity. Cancer Res 1977;37:572-7.
57. Hunter CA, Yu D, Gee M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166:5878-81.
58. Thomas-Tikhonenko A, Hunter CA. Infection and cancer: the common vein. Cytokine Growth Factor Rev 2003;14:67-77.
59. Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996;56:2434-9.
60. Mizutani Y, Bonavida B, Koishihara Y, et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590-6.
61. Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809-18.
62. Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994;120:471-8.
63. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996;88:1383-92.
64. Fujisawa T, Yamaguchi Y. Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma. Cancer 1996;78:1892-8.
65. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191-9.
66. Sandoval BA, Robinson AV, Sulaiman TT, et al. Open versus laparoscopic surgery: a comparison of natural antitumoral cellular immunity in a small animal model. Am Surg 1996;62:625-30; discussion 630-1.
67. Kutza J, Gratz I, Afshar M, Murasko DM. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Anesth Analg 1997;85:918-23.
68. Page GG, Ben-Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241-50.
69. Knottenbelt CM, Simpson JW, Tasker S, et al. Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract 2000;41:393-7.
70. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-5.
71. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-6.
72. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-8.
73. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-8.
74. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-8.
75. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-6.
76. Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 1997;80:2263-7.
77. Seay TM, Peretsman SJ, Dixon PS. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 1996;155:757-62.
78. Miclau T, Edin ML, Lester GE, et al. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998;16:509-12.
79. Holtom PD, Pavkovic SA, Bravos PD, et al. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res 2000;18:721-7.
80. Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anti-Canc Agents 2003;3:439-50.